Obesity recognition ‘going in right direction’ amid GLP-1 revolution, but obstacles remain
ATLANTA — The use of GLP-1 drugs to treat obesity has cause awareness of the complex medical condition to surge. But the cost of treating it also puts the health care system in a bind. Dr. Scott Kahan, director of the National Center for Weight & Wellness and a faculty member at the Johns Hopkins Bloomberg…
Cardio-renal Outcomes in Type 2 Diabetes Patients with Advanced Chronic Kidney Disease on SGLT2 inhibitors or GLP-1 receptor agonists
GLP-1 RA and SGLT2i have demonstrated cardio-renal protective effects in randomized clinical trials. However, their comparative cardio-renal benefits in diabetes patients with stage 4–5 chronic kidney disease remain underexplored.
Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals
SAN MATEO, Calif.–(BUSINESS WIRE)–Evidation, the leader in direct-from-participant real-world data and health research, is announcing new preliminary insights suggesting that nearly 1 in 7 injectable GLP-1 users are microdosing, that microdosing is largely patient-driven, and that there are multiple relevant influences driving microdosing decisions. Evidation has been conducting ongoing, multimodal, participant-consented research within a discrete […]
Shed Launches Three New Wellness Solutions: Microdose GLP-1, NAD+ and Glutathione for Energy, Clarity, and Healthy Aging
SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ — Shed, the wellness brand known for health and weight-loss solutions, has launched three new products to support long-term health: Tirzepatide Microdose GLP-1 injections, oral NAD+ tablets and Glutathione injections. These offerings build on…
IJMS, Vol. 26, Pages 12130: The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition
IJMS, Vol. 26, Pages 12130: The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition International Journal of Molecular Sciences doi: 10.3390/ijms262412130 Authors: Lampros Chrysavgis Niki Gerasimoula Mourelatou Maria-Evangelia Koloutsou Sophia Rozani Evangelos Cholongitas Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and newer incretin-based co-agonists have transformed obesity and type 2 […]
Cells, Vol. 14, Pages 2009: Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice
Cells, Vol. 14, Pages 2009: Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice Cells doi: 10.3390/cells14242009 Authors: Natassia Rodrigo Dunja Aksentijevic Nikayla Patel Carol A. Pollock Lana McClements Sarah J. Glastras Background: The placenta stands at the maternal–fetal interface and is a key organ regulating the intrauterine environment. In pregnancies exposed to […]
Are Doctors Trained To Treat Obesity? Dr. Scott Kahan On GLP-1 & Public Health | RAISING AMERICA
In this episode of Raising America, Elizabeth Prann sits down with Director of the National Center for Weight and Wellness, Scott Kahan. He is a physician trained in clinical medicine and public health and an internationally recognized specialist in Obesity Medicine. He is Director of the National Center for Weight and Wellness and has held […]
GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top Research
(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes. In a phase III trial…
Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process
Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process Pharmaceuticals doi: 10.3390/ph18121896 Authors: Rolan R. Shaifutdinov Maria V. Sinegubova Ivan I. Vorobiev Polina E. Prokhorova Alexey B. Podkorytov Nadezhda A. Orlova Background: Dulaglutide, a GLP-1-IgG4 Fc fusion, is a long-acting GLP-1 receptor agonist […]
OrsoBio obesity data; Monte Rosa’s prostate cancer pill; Development pacts for Adaptive and SandboxAQ
Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide, OrsoBio’s oral obesity drug TLC-6740 led to an additional …